

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**


(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/932,538
		Filing Date	August 17, 2001
		First Named Inventor	Steve J.D. Bell
		Art Unit	1645
		Examiner Name	Zeman, Robert A.
To: Number of Pages in This Submission		Attorney Docket Number	37070/205236


ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) ____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): -Form PTO/SB/08 (3 sheets) -47 Publications -Return Receipt Postcard
<div style="border: 1px solid black; padding: 5px; min-height: 50px;"> Remarks </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Catherine E. Fienning, Registration No. 54,095 Kilpatrick Stockton LLP
Signature	
Date	August 13, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Emily Guida		
Signature		Date	August 13, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**FEE TRANSMITTAL
for FY 2004**

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180**Complete if Known**

Application Number	09/932,538
Filing Date	August 17, 2001
First Named Inventor	Steve J.D. Bell
Examiner Name	Zeman, Robert A.
Art Unit	1645
Attorney Docket No.	37070/205236

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money ☐ Other ☐ None
 Order

☒ Deposit Account:
 Deposit
Account
Number 11-0855

 Deposit
Account
Name KILPATRICK STOCKTON LLP

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee
 to the above-identified deposit account.

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$ 0)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Total Claims	Extra Claims	Fee from below	Fee Paid
	20 **	0	X	0
Independent Claims	3 **	0	X	0
Multiple Dependent			X	0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$ 0)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$ 180)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Catherine E. Fienning	Registration No. (Attorney/Agent)	54,095	Telephone	404-532-6938
Signature				Date	August 13, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Steve Bell, et al.) Group Art Unit: 1645
)
Serial No.: 09/932,538) Examiner: Zeman, Robert A.
)
Filed: August 17, 2001)
)
For: CALCIUM PHOSPHATE PARTICLES)
AS MUCOSAL ADJUVANTS)

Attorney Docket No. 37070/205236

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

Date: August 13, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97 and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the enclosed Form PTO/SB/08 are submitted for consideration by the Examiner. Copies of the cited documents are enclosed.

Submission of the references provided in this Information Disclosure is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specially designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made, or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed before the issuance of an action closing prosecution (37 C.F.R. 1.97(c)). Applicants enclose a check in the amount of \$180.00,


08/18/2004 WABDELRI 00000108 09932538

180.00 0P
01 FC:1806

U.S. Serial No. 09/932,538
Filed: August 17, 2001
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


the fee for consideration of this paper. The Commissioner is authorized to charge any additional fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,



Catherine E. Fienning
Reg. No. 54,095
ATTORNEY FOR ASSIGNEE

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-532.6938



Substitute for form 1449A (Rev. 10/01)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/932,538
Filed	August 17, 2001
First Named Inventor	Bell, et al.
Group Art Unit	1645
Examiner Name	ZEMAN, Robert A.
Attorney Docket Number	37070/205236

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		3,382,150	05/07/68	Grass, et al.	
		3,983,229	09/28/76	Relyveld	
		4,070,454	01/24/78	Relyveld	
		4,075,321	02/21/78	Relyveld	
		4,625,019	11/25/86	Relyveld	
		4,929,774	05/29/90	Fukamachi, et al.	
		5,318,913	06/07/94	Relyveld	
		5,469,599	11/28/95	Wurdack	
		6,024,987	02/15/00	Santos, et al.	
		2001/0021389 A1	09/13/01	Starling, et al.	
		2002/0068090 A1	06/06/02	Bell, et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		0 715 846 A	06/12/96	Europe		
		0 326 026 A	08/02/89	Europe		
		WO 99/03451	01/1999	WIPO		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Alward, "Medical Management of Glaucoma," <i>N. Eng. J. Med.</i> , 339:1298-1307 (1998)	
		Bochot, et al., "Intravitreal delivery of oligonucleotides by sterically stabilized liposomes," <i>Invest. Ophthalmol. Vis. Sci.</i> , 43(1):253-259 (2002)	
		Bousquet, et al., "Allergen immunotherapy : therapeutic vaccines for allergic diseases," <i>Annals of Allergy, Asthma & Immunology</i> , 81:401-405 (1998)	
		Bousquet, "Allergy Tests and Therapy," <i>Allergy Tests and Therapy, The Buyer's Guide to Respiratory Care Products</i> , pp. 8-10 (undated)	
		Brubaker, "Measurement of aqueous flow by fluorophometry," <i>In Glaucoma</i> , Ritch, et al., Editors, Mosby, St. Louis, pp. 337-344 (1989)	
		Brubaker, "Mechanism of Action of Bimatoprost (Lumigan TM)," <i>Survey of Ophthalmology</i> , 45(4):S347-S351 (2001)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1490

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3


Complete if Known

Application Number	09/932,538
Filed	August 17, 2001
First Named Inventor	Bell, et al.
Group Art Unit	1645
Examiner Name	ZEMAN, Robert A.
Attorney Docket Number	37070/205236

	Chu, et al., "Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: A dopamine ₃ receptor agonist," <i>J. of Pharmacology and Experimental Therapeutics</i> , 293(3):710-716 (2000)	
	Chu, et al., "Potential sites of action of TNPA: A dopamine-2 receptor agonist," <i>Exp. Eye Res.</i> , 69:611-616 (1999)	
	Chu, et al., "Biodegradable Calcium Phosphate Nanoparticles as a New Vehicle for Delivery of a Potential Ocular Hypotensive Agent," <i>J. of Ocular Pharmacology and Therapeutics</i> , 18(6):507-514 (2002)	
	De Campos, et al., "Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A," <i>Int. J. Pharm.</i> , 224:159-168 (2001)	
	Goto, et al., "Toxicity of Aluminum Compounds as an Adjuvant for Vaccines," <i>Aluminum Toxicity in Infants' Health and Disease</i> , Chapter 15, pp. 208-224 (1997)	
	Goto, et al., "Studies on the toxicities of aluminum hydroxide and calcium phosphate as immunological adjuvants for vaccines," <i>Vaccine</i> , 11 :914-918 (1993)	
	Gupta, et al., "Adjuvant Properties of Aluminum and Calcium Compounds," <i>Vaccine Design</i> , 229-248 (1995)	
	Hoyng, et al., "Pharmacological therapy for glaucoma," <i>Drugs</i> , 59(3):411-434 (2000)	
	Jiao, et al., <i>Hum. Gene Therapy</i> , 3:21 (1992)	
	Lamprecht, et al., "Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease," <i>J. Pharm. Exper. Thera.</i> 299(2):775-781 (2001)	
	Lery, "Haemolytic activity of calcium phosphate adjuvant," <i>Vaccine</i> , 12(5):475	
	Li, et al., "Ocular drug delivery of progesterone using nanoparticles," <i>J. Microencapsul.</i> , 3(3):213-218 (1986)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	09/932,538
Filed	August 17, 2001
First Named Inventor	Bell, et al.
Group Art Unit	1645
Examiner Name	ZEMAN, Robert A.
Attorney Docket Number	37070/205236

	Montgomery, et al., "Heterologous and Homologous Protection Against Influenza A by DNA Vaccination: Optimization of DNA Vectors," <i>DNA and Cell. Biol.</i> , 12:777-783 (1993)	
	Neefjes, et al., "Cell Biology of Antigen Presentation," <i>Curr. Opin. Immunolo.</i> , 5(1):27-34 (1993)	
	Ogidigben, et al., "Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits," <i>J. of Ocular Pharmacology</i> , 9(3):187-199 (1993)	
	Ogidigben, et al., "Ocular hypotensive action of a dopaminergic (DA ₂) agonist, 2,10,11-trihydroxy-N-n-propylnoraporphine," <i>J. Pharmacol. Exp. Ther.</i> , 267:822-827 (1993)	
	O'Hehir, "Immunology and allergy," <i>The Medical Journal of Australia</i> , 176(1):22 (2002)	
	Potter, "Do dopamine and dopamine receptors have roles in modulating function in the anterior segment? The evidence." <i>In Progress in Retinal and Eye Research</i> , Osborne, N.N. and Chader, G.J, Editors, Elsevier Sciences Ltd., New York, pp 103-111 (1995)	
	Relyveld, et al., "Calcium Phosphate Adjuvanted Allergens," <i>Annals of Allergy</i> , 54:521-528 (1985)	
	Relyveld, et al., "Preparation and Use of Calcium Phosphate Adsorbed Vaccines," <i>Develop. Biol. Standard</i> , 65:131-136 (1986)	
	Rolland, "New Vaccines for Allergic Rhinitis," Department of Pathology and Immunology, Monash University Medical School, Alfred Hospital, Melbourne, Australia, 2 pages (undated)	
	Service, "Drug Delivery Takes a Deep Breath," <i>Science</i> , 277:5330 (1997)	
	Yablonski, et al., "A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics," <i>Exp. Eye Res.</i> , 27:135-142 (1978)	
	Academic Press Dictionary of Science and Technology, http://www.harcourt.com/dictionary/def/2/2/3/1/2231200.html , No. 2000 (11/03/00)	
	Food and Drug Administration Center for Drugs and Biologics Summar Minutes Allergenic Products Advisory Committee Meeting 5, 13 pages, June 25-26, 1987	
	Ickovic, et al, "Calcium-Phosphate-Adjuvanted Allergens : Total and Specific IgE Levels Before and After Immunotherapy with House Dust and Dermatophagoides Pternoyssiuns Extracts," <i>Ann. Immunolo. (Inst. Pasteur)</i> 1983; 134(D) :385-398	
	Patent Abstracts of Japan & JP 09 208491 A (Ashai Optical) 12 August 1997	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.